VBI VACCINES INC. (TSE:VBV) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On February 22, 2017, VBI Vaccines Inc. issued a press release. A
copy of the press release is furnished herewith as Exhibit 99.1
and incorporated by reference in this Item 7.01.
The information disclosed under this Item 7.01, including Exhibit
99.1 hereto, shall not be deemed filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, and shall not
be deemed filed with the U.S. Securities and Exchange Commission
nor incorporated by reference into any filing made under the
Securities Act of 1933, as amended, except as expressly set forth
by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated February 22, 2017* |
*Furnished herewith
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda). VBI VACCINES INC. (TSE:VBV) Recent Trading Information
VBI VACCINES INC. (TSE:VBV) closed its last trading session 00.00 at 6.32 with 9,776 shares trading hands.
